Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden

Åsa Ericsson, Adam Lundqvist, Åsa Ericsson, Adam Lundqvist

Abstract

Background: Patients with uncontrolled type 2 diabetes mellitus (T2DM) are a priority group for intensified therapy without weight gain and with low risk of hypoglycaemia.

Objective: This study evaluates the cost effectiveness of insulin degludec plus liraglutide (IDegLira, Xultophy®) compared with six potential intensification treatment options for patients with T2DM that is uncontrolled with basal insulin.

Methods: The Swedish Institute for Health Economics (IHE) Cohort Model of Type 2 Diabetes was used with Swedish input data, a 40-year time frame and a societal perspective. The comparators for treatment intensification included insulin glargine, neutral protamine Hagedorn (NPH) insulin, insulin aspart plus either glargine or NPH, and liraglutide plus either glargine or NPH. Clinical data for all comparators (except NPH insulin) were based on an indirect treatment comparison of several studies. Prices were obtained from the 2014 Swedish Dental and Pharmaceutical Benefits Agency (Tandvårds- och läkemedelsförmånsverket [TLV]) database, and utility values were obtained from published studies. Sensitivity analyses were undertaken.

Results: Overall incremental cost-effectiveness ratios (ICER) were Swedish krona (SEK) 70,000 or lower per quality-adjusted life-year (QALY). IDegLira compared with intensified basal insulin showed an ICER of SEK 28,000 per QALY versus insulin glargine, SEK70,000 per QALY versus NPH insulin and SEK 60,000 per QALY versus NPH insulin plus liraglutide. IDegLira was dominant over insulin glargine plus liraglutide and insulin aspart plus insulin glargine or NPH insulin. Results were driven by the difference in glycated haemoglobin (HbA1c) reduction between treatments, as confirmed by sensitivity analyses.

Conclusions: IDegLira is estimated to be a cost-effective treatment in Sweden compared with commonly used intensification treatments for patients with T2DM uncontrolled with basal insulin.

Conflict of interest statement

Funding

This study was funded by Novo Nordisk Scandinavia AB, the manufacturer of IDegLira.

Conflict of interest

Åsa Ericsson is an employee of Novo Nordisk Scandinavia AB. Adam Lundqvist is an employee at IHE and declares no conflicts of interest.

References

    1. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412. doi: 10.1136/bmj.321.7258.405.
    1. American Diabetes Association Standards of medical care in diabetes: 2008. Diabetes Care. 2008;31(Suppl 1):S12–S54. doi: 10.2337/dc08-S012.
    1. Socialstyrelsen. Nationella riktlinjer för diabetesvården 2010 – Stöd för styrning och ledning 2010. . Accessed 22 Dec 2016.
    1. International Diabetes Federation. Global guideline for type 2 diabetes 2012. . Accessed 22 Dec 2016.
    1. National Diabetes Register. NDR Statistik. . Accessed 22 Dec 2016.
    1. Socialstyrelsen. Nationella riktlinjer för diabetesvård: Stöd för styrning och ledning: Preliminär version 2014. . Accessed 22 Dec 2016.
    1. National Diabetes Register (NDR). Årsrapport, 2013 års resultat 2013. . Accessed 22 Dec 2016.
    1. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26(6):1902–1912. doi: 10.2337/diacare.26.6.1902.
    1. Frier BM. How hypoglycaemia can affect the life of a person with diabetes. Diabetes Metab Res. 2008;24(2):87–92. doi: 10.1002/dmrr.796.
    1. Ostenson CG, Geelhoed-Duijvestijn P, Lahtela J, Weitgasser R, Markert Jensen M, Pedersen-Bjergaard U. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med. 2014;31(1):92–101. doi: 10.1111/dme.12261.
    1. Östenson CG, Geelhoed-Duijvestijn PHLM, Jensen MM, Pedersen-Bjergaard U. DB4 patient-reported hypoglycaemia in real-world settings in seven European countries. Value Health. 2012;15(7):A277. doi: 10.1016/j.jval.2012.08.471.
    1. Khunti K, et al., editors. Hypoglycaemia among insulin-treated patients with diabetes: an international retrospective and prospective study of 3832 patients. World Diabetes Congress, 2-6 December 2013, Melbourne, Australia.
    1. Jönsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health. 2006;9(3):193–198. doi: 10.1111/j.1524-4733.2006.00100.x.
    1. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet. 1998;352(9131):837–853. doi: 10.1016/S0140-6736(98)07019-6.
    1. Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Nunez L, Gudbjornsdottir S, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52(1):65–73. doi: 10.1007/s00125-008-1190-x.
    1. Odegaard K, Borg S, Persson U, Svensson M. The Swedish cost burden of overweight and obesity—evaluated with the PAR approach and a statistical modelling approach. Int J Pediatr Obes. 2008;3(Suppl 1):51–57. doi: 10.1080/17477160801897067.
    1. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682–689. doi: 10.1111/j.1464-5491.2012.03605.x.
    1. Dushay J, Abrahamson MJ. Insulin therapy for type 2 diabetes: making it work. J Fam Pract. 2010;59(4):E1–E8.
    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012;35(6):1364–1379. doi: 10.2337/dc12-0413.
    1. Socialstyrelsen. National Guidelines for Diabetes Care. . Accessed 22 Dec 2016.
    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–149. doi: 10.2337/dc14-2441.
    1. Tandvårds- och läkemedelsförmånsverket (TLV). General guidelines for economic evaluations from the Pharmaceutical Benefits Board (LFNAR 2003:2) 2003. . Accessed 22 Dec 2016.
    1. Socialstyrelsen. Nationella riktlinjer för diabetesvård. . Accessed 22 Dec 2015.
    1. Lundqvist A, Steen Carlsson K, Johansen P, Andersson E, Willis M. Validation of the IHE cohort model of Type 2 diabetes and the impact of choice of macrovascular risk equations. PloS One. 2014;9(10):e110235. doi: 10.1371/journal.pone.0110235.
    1. Ahmad Kiadaliri A, Gerdtham UG, Nilsson P, Eliasson B, Gudbjornsdottir S, Carlsson KS. Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data. PloS One. 2013;8(5):e62650. doi: 10.1371/journal.pone.0062650.
    1. Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925–1933. doi: 10.1007/s00125-013-2940-y.
    1. Freemantle N, Mamdani M, Vilsboll T, Kongso JH, Kvist K, Bain SC. IDegLira versus alternative intensification strategies in patients with Type 2 diabetes inadequately controlled on basal insulin therapy. Diabetes Ther. 2015;6(4):573–591. doi: 10.1007/s13300-015-0142-y.
    1. Buse JB, Vilsboll T, Thurman J, Blevins TC, Langbakke IH, Bottcher SG, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) Diabetes Care. 2014;37(11):2926–2933. doi: 10.2337/dc14-0785.
    1. Ahmann AJ, et al., Efficacy and safety of liraglutide vs. placebo when added to basal insulin analogs in patients with type 2 diabetes (LIRAADD2BASAL): 331-OR. Diabetes. 2014;63(Suppl 1):1056–64.
    1. Garber AJ, King AB, Del Prato S, Sreenan S, Balci MK, Munoz-Torres M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal–bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal–Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379(9825):1498–1507. doi: 10.1016/S0140-6736(12)60205-0.
    1. Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care. 2013;36(4):858–864. doi: 10.2337/dc12-1668.
    1. . Comparison of NN5401 With insulin glargine, both in combination with oral antidiabetic drugs, in subjects with type 2 diabetes (BOOST™) 2015. . Accessed 22 Dec 2016.
    1. Tandvårds- och läkemedelsförmånsverket (TLV). Tresiba Tandvårds- och läkemedelsförmånsverket reimbursement application. 2013. . Accessed 22 Dec 2016.
    1. Socialstyrelsen. Diabetesvård—Rekommendationer, bedömningar och sammanfattning. 2015. . Accessed 22 Dec 2016.
    1. Moberg E. Diabetes. 2016. . Accessed 22 Dec 2016.
    1. Statistics Sweden. CPI, indices for main groups, annual averages. . Accessed 22 Dec 2016.
    1. Tandvårds—och läkemedelsförmånsverket (TLV). Databas för beslut 2014 [5 September]. . Accessed 22 Dec 2016.
    1. Devries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev. 2007;23(6):441–454. doi: 10.1002/dmrr.762.
    1. Geelhoed-duijvestijn PHLM, Pedersen-bjergaard U, Jensen MM, Östenson CG. PDB47 effects of patient-reported non-severe hypoglycaemia on health care resource use and work-time loss in seven European countries. Value Health. 2012;15(7):A502. doi: 10.1016/j.jval.2012.08.1690.
    1. Steen Carlsson K, Persson U. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin. J Med Econ. 2014;17(9):658–669. doi: 10.3111/13696998.2014.933110.
    1. Statistics Sweden. Average monthly salary by sector 1992–2013. . Accessed 22 Dec 2016.
    1. Sørensen J, Jon Plough U. The cost of diabetes-related complications: registry-based analysis of days absent from work. Econ Res Int. 2013;2013:8. doi: 10.1155/2013/618039.
    1. Evans M, Ridderstråle M, Jensen HH, Bøgelund M, Jensen MM, Ericsson Å, et al., editors. PDB108: quantifying the short-term impact of changes in HbA1c, weight and insulin regimen on health related quality-of-life. ISPOR 18th Annual European Congress, 2015, Milan, Italy.
    1. Evans M, Jensen HH, Bogelund M, Gundgaard J, Chubb B, Khunti K. Flexible insulin dosing improves health-related quality-of-life (HRQoL): a time trade-off survey. J Med Econ. 2013;16(11):1357–1365. doi: 10.3111/13696998.2013.846262.
    1. Kiadaliri A, Gerdtham U-G, Eliasson B, Gudbjörnsdottir S, Svensson A-M, Carlsson K. Health utilities of type 2 diabetes-related complications: a cross-sectional study in Sweden. Int J Environ Res Public Health. 2014;11(5):4939–4952. doi: 10.3390/ijerph110504939.
    1. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14(3):217–230. doi: 10.1002/hec.910.
    1. Lane S, Levy AR, Mukherjee J, Sambrook J, Tildesley H. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin. 2014;30(7):1267–1273. doi: 10.1185/03007995.2014.899207.
    1. Evans M, Khunti K, Mamdani M, editors. Health-related quality of life associated with daytime and nocturnal hypoglycemic events: a time trade-off survey oral presentation 135. American Diabetes Association 72nd Annual Scientific Sessions, 8–12 June 2012, Philadelphia, USA.
    1. Evans M, Khunti K, Mamdani M, Galbo-Jorgensen CB, Gundgaard J, Bogelund M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11:90. doi: 10.1186/1477-7525-11-90.
    1. Henry RR, et al., DURATION-1 extension: Efficacy and tolerability of exenatide once weekly (qw) over 6 years in patients with T2DM. Poster presentation 964-P. Presented at the American Diabetes Association 74nd Annual Scientific Sessions, San Francisco; 13-17 June 2014. , 2014. Accessed 22 Dec 2016.
    1. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124(1 Pt 2):136–145. doi: 10.7326/0003-4819-124-1_Part_2-199601011-00011.
    1. Ward AJ, Salas M, Caro JJ, Owens D. Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the UK. Cost Eff Resour Alloc. 2004;2(1):2. doi: 10.1186/1478-7547-2-2.
    1. National Institute for Health and Care Excellence (NICE). NICE DSU Technical support document 1: introduction to evidence synthesis for decision making 2012. . Accessed 22 Dec 2016.
    1. Institut fur Qualitat und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). General methods 4.2. 2015. . Accessed 22 Dec 2016.
    1. Haute Autorite de Sante (HAS). Choices in methods for economic evaluation 2012. . Accessed 22 Dec 2016.
    1. Davies MJ, Glah D, Chubb B, Konidaris G, McEwan P. Cost effectiveness of IDegLira vs. alternative basal insulin intensification therapies in patients with type 2 diabetes mellitus uncontrolled on basal insulin in a UK setting. PharmacoEconomics. 2016;34(9):953–966. doi: 10.1007/s40273-016-0433-9.
    1. McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE diabetes model. Value Health. 2014;17(6):714–724. doi: 10.1016/j.jval.2014.07.007.
    1. Ridderstråle M, Evans LM, Jensen HH, Bøgelund M, Jensen MM, Ericsson Å, et al. Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. Health Qual Life Outcomes. 2016;14(1):1–10. doi: 10.1186/s12955-016-0411-0.
    1. McQueen RB, Ellis SL, Maahs DM, Anderson HD, Nair KV, Libby AM, et al. Association between glycated hemoglobin and health utility for type 1 diabetes. Patient. 2014;7(2):197–205. doi: 10.1007/s40271-014-0045-4.
    1. X-Rates. Swedish krona historic exchange rates look-up 2016. . Accessed 24 Nov 2016.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren